To the full analysis
Buyback calculator for Capricor Therapeutics
Capricor Therapeutics stock: key metrics
CAPRCapricor Therapeutics had an operating margin of 0% and a return on invested capital (ROIC) of −36% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 100.0% | −656.0% | −678.0% |
| 2007 | 100.0% | −9,368.8% | −10,160.7% |
| 2008 | no data | no data | no data |
| 2009 | no data | no data | no data |
| 2010 | no data | no data | no data |
| 2011 | 100.0% | −361.5% | −360.5% |
| 2012 | 100.0% | −1,248.1% | −968.3% |
| 2013 | 100.0% | −1,371.7% | −1,767.0% |
| 2014 | −72.0% | −144.4% | −149.2% |
| 2015 | −264.3% | −334.0% | −340.5% |
| 2016 | −402.9% | −532.2% | −589.6% |
| 2017 | 100.0% | −482.4% | 91.2% |
| 2018 | 100.0% | −917.2% | −909.1% |
| 2019 | −411.6% | −769.5% | −760.4% |
| 2020 | 100.0% | −4,412.6% | −4,401.9% |
| 2021 | 100.0% | −8,549.9% | −8,175.9% |
| 2022 | −755.1% | −1,163.9% | −1,137.4% |
| 2023 | −44.8% | −95.6% | −88.5% |
| 2024 | −124.4% | −191.1% | −181.7% |
| 2025 | no data | no data | no data |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | 200.0% | no data | 0.0% |
| 2007 | −67.8% | −98.8% | −60.3% |
| 2008 | −100.0% | no data | −100.0% |
| 2009 | −100.0% | no data | −100.0% |
| 2010 | −100.0% | no data | −100.0% |
| 2011 | −100.0% | no data | −100.0% |
| 2012 | −38.7% | −67.3% | −34.9% |
| 2013 | 200.0% | no data | −100.0% |
| 2014 | 99.5% | −87.9% | −45.6% |
| 2015 | 200.0% | no data | −80.0% |
| 2016 | 200.0% | no data | −100.0% |
| 2017 | 21.7% | −90.4% | 14.9% |
| 2018 | −100.0% | no data | −100.0% |
| 2019 | −100.0% | −67.1% | −68.8% |
| 2020 | −48.4% | −51.4% | −39.4% |
| 2021 | −63.8% | −47.6% | −48.4% |
| 2022 | −100.0% | −72.4% | −57.9% |
| 2023 | −98.6% | −68.7% | −37.9% |
| 2024 | −27.8% | −37.7% | −23.7% |
| 2025 | −34.4% | −36.0% | −29.5% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 20 Mar 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.